From obesity to brain diseases...expansion of GLP-1 agonists
By Son, Hyung-Min | translator Kang, Shin-Kook
24.07.11 05:11:50
가나다라
0
BIX 2024 held on the 10th... a session held on various uses of GLP-1
Hanmi and Dong-A ST are developing new obesity drugs with new modes of action
Companies challenge the field of degenerative brain diseases...sees possibility in MASH

▲In-Young Choi, Head of R&D at Hanmi Pharmaceutical
The domestic pharmaceutical bio industry is looking into the possibility of developing various new drugs with GLP-1 agents. As Novo Nordisk and Lilly's GLP-1-based obesity drugs have become global blockbusters, latecomers are also avidly developing jumping in to develop the next blockbuster. Major domestic companies are conducting clinical studies on the use of GLP-1 agents not only for obesity, focusing on the mode of administration and quality of weight loss effects, but also in the field of degenerative brain diseases such as metabolism-associated steatohepatitis (MASH) and Alzheimer's disease.
On July 10, the Korea Biotechnology Industry Association and RX Korea hosted the BIOPLUS-INTERPHEX KO
Son, Hyung-Min(shm@dailypharm.com)
If you want to see the full article, please JOIN US (click)